Jasper Therapeutics, Inc. (JSPR) Company Overview

What does Jasper Therapeutics do after the Kira merger?

Jasper Therapeutics, Inc. is a Nasdaq-listed clinical-stage biotechnology company, trading under JSPR, that is being rebuilt around a broader immunology pipeline. Before July 2026, Jasper was essentially a single-asset company centered on briquilimab, an anti-KIT antibody designed to remove mast cells or clear hematopoietic stem-cell niches. On July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals and added complement and B-cell programs. The result is not a commercial pharmaceutical company with recurring sales; it is a research organization whose value depends on clinical evidence, regulatory progress, intellectual property, capital access, and partnering.

The current company therefore has three scientific engines. KP-104 targets both the alternative and terminal complement pathways; briquilimab targets KIT in transplant and mast-cell biology; and KP-701 is designed to engage CD79B and CD32B to suppress pathogenic B-cell activity. Two other Kira assets, KP-301 and KP-402, were licensed to Mirador Therapeutics for a $12 million upfront payment plus potential milestones and royalties. Jasper's official company website still explains the anti-KIT foundation, while the July transaction materials define the broader combined-company strategy.

How does Jasper make money before product approval?

No commercial revenue today

Jasper has not generated product revenue and does not expect commercial sales unless a candidate completes development and receives regulatory approval. That distinction is fundamental. Equity offerings, preferred-stock financings, warrants, and cash received in a merger are financing inflows, not operating revenue. A lower quarterly net loss can also be misleading because warrant-liability remeasurement may create a non-cash accounting gain without improving clinical productivity or cash generation.

Licensing can monetize assets without building a sales force

The Mirador agreement illustrates the capital-efficient branch of Jasper's model. Kira out-licensed KP-301 and KP-402 for $12 million upfront, up to $108.5 million of development and regulatory milestones, up to $350 million of commercial milestones, and low- to mid-single-digit royalties. These are contractual possibilities, not forecast revenue. Still, they show how a small biotechnology company can narrow internal spending while retaining contingent economics in non-core programs.

Which pipeline assets matter most?

KP-104 now leads the catalyst calendar

The July 2026 transaction moved KP-104 to the center of Jasper's near-term narrative. The molecule combines an anti-C5 monoclonal antibody with a factor-H-related component, seeking broader complement control than a single-pathway inhibitor. Kira's official KP-104 program page describes Phase 2 work across IgA nephropathy, C3 glomerulopathy, systemic-lupus-associated thrombotic microangiopathy, and PNH. The combined company expects interim Stage 1 renal data in Q4 2026, updated Stage 1 and interim Stage 2 data in Q2 2027, and a PNH regulatory update in the first half of 2027.

Briquilimab's role changed, but the asset remains consequential

Briquilimab was previously being prepared for a Phase 2b CSU study, but capital constraints drove a strategic review before that program began. After the merger, management emphasized SCID conditioning and said it expects to disclose next steps after a pre-BLA meeting in Q1 2027, while reassessing mast-cell-disease development in the second half of 2026. That pivot is important: the antibody's most valuable path may be a rare-disease regulatory route rather than a broad, expensive chronic-urticaria program.

KP-701 adds a different mechanism and time horizon

KP-701 is earlier and therefore more speculative. Management expects a CTA or IND filing in Q1 2027 and first-in-human data in Q3 2027. The official combined pipeline description places it in autoantibody-mediated disorders. In portfolio terms, KP-701 reduces single-mechanism concentration, but it also adds preclinical spending and execution risk.

What strategic turning points created today's Jasper?

Jasper's history is best understood as repeated portfolio and financing resets rather than a smooth march toward commercialization. The current company combines Stanford-origin anti-KIT biology, a 2021 public-market transaction, a 2025 retrenchment, and Kira's complement platform.

1. 2013
   Amgen and Stanford began investigator-sponsored work involving the antibody later known as briquilimab, establishing the translational foundation for stem-cell conditioning.
2. 2018
   The private Jasper operating company was incorporated, creating a dedicated vehicle for anti-KIT development.
3. 2019
   Jasper obtained a worldwide exclusive Amgen license for briquilimab, making licensed intellectual property the core asset.
4. 2021
   The merger with Amplitude Healthcare Acquisition Corporation made Jasper public and supplied capital for development.
5. July 2025
   A roughly 50% workforce reduction, halted asthma enrollment, discontinued transplant programs, and vivarium closure narrowed the company to chronic urticarias and preserved cash.
6. January 2026
   Updated CSU data showed 4 of 6 additional briquilimab-treated patients achieved complete response at week 12, partially repairing confidence after anomalous 2025 cohorts.
7. June 2026
   The board initiated a strategic-alternatives review because legacy cash was insufficient for the planned development program.
8. July 2026
   Jasper acquired Kira, arranged a $132 million PIPE, licensed two assets to Mirador, and transformed into a multi-asset immunology company.

The 2025 Form 10-K documents the license structure, competitive set, restructuring, and historical financial burden. The July 2026 merger Form 8-K is the more relevant source for today's ownership and pipeline. Together they show why historical Jasper financial statements cannot be projected mechanically into the new company.

What do the latest financials show?

Legacy Jasper entered the transaction with severe liquidity pressure

The March 31, 2026 balance sheet describes legacy Jasper before the Kira merger and PIPE. Cash fell from $28.7 million at December 31, 2025 to $14.1 million at March 31, 2026. First-quarter operating cash use was $14.5 million, nearly equal to the quarter-end cash balance. Management therefore stated that available cash was not sufficient to fund at least twelve months of operations. The July financing is not a small supplement to that balance sheet; it is the transaction that made continued development possible.

Cash burn matters more than the reported Q1 net loss

Program spending shows the effects of retrenchment

The latest Q1 2026 Form 10-Q is the correct source for the legacy balance sheet. The July merger release is the correct source for the expected post-transaction runway. A serious model must bridge the two rather than treating the March cash balance as the combined company's current liquidity.

Why does the Kira merger change the financial and ownership story?

The merger solved two immediate problems: Jasper lacked enough cash to launch its planned CSU study, and its value was concentrated in briquilimab. Kira contributed a broader pipeline, while the concurrent financing supplied approximately $132 million of gross proceeds. A subsequent SEC Form 4 states that the private placement closed on July 20, 2026. Management expects combined cash, the PIPE, and the $12 million Mirador upfront payment to fund operations through the second half of 2028.

The dilution is economically central, not a footnote

Pre-transaction Jasper holders retain only 6.68% of the fully diluted, as-converted company. The disclosed as-converted share count is approximately 653.6 million, compared with roughly 28.0 million voting common shares outstanding before the merger. That dilution is the price of obtaining Kira's assets and a multi-year runway. It also means historical per-share metrics, option counts, and ownership percentages are no longer decision-useful without a pro forma share bridge.

The official merger announcement provides the pipeline milestones, financing size, runway estimate, and ownership split. Investors still need to monitor stockholder approval for conversion of the non-voting preferred stock and the amendment needed to increase authorized common shares.

What gives Jasper a competitive advantage?

Mechanistic differentiation is the main moat

Jasper has no commercial scale, installed base, brand moat, or switching costs. Its defensibility must come from differentiated biology, clinical data, patents, manufacturing know-how, and regulatory positioning. KP-104 is designed to inhibit two complement pathways with one molecule. Briquilimab attacks KIT biology through mast-cell depletion and stem-cell-niche clearance. KP-701 seeks to suppress B-cell activity through a paired receptor mechanism. These are scientifically specific advantages, but they remain hypotheses until replicated in larger controlled trials.

Competition is broad and well financed

Jasper's 2025 filing identified direct or adjacent briquilimab competitors across antibodies, small molecules, cytokine-pathway biologics, and mast-cell signaling. The combined company also enters an established complement field where approved therapies and larger developers have regulatory, commercial, and manufacturing advantages. Jasper's opportunity is differentiation, not category ownership.

Who owns Jasper stock, and who controls the next chapter?

The pre-merger shareholder register is no longer the economic map

The June 2026 proxy showed a dispersed one-share-one-vote common-stock structure. Velan Capital and affiliates held 9.9%, Integrated Core Strategies held 5.8%, Acorn Capital Advisors held 5.3%, and current directors and executive officers as a group held 2.3%. Those figures remain historically useful, but the Kira merger and PIPE radically changed fully diluted economics. Former Kira holders and new financing investors together account for 93.32% of the as-converted company.

Governance now includes conversion and authorization decisions

The combined board has six members: Jeet Mahal, Patrick Crutcher, Tom Wiggans, Judith Shizuru, Svetlana Lucas, and Kurt von Emster. Preferred stock issued in the merger and PIPE is non-voting until conversion, and each preferred share is designed to convert into 61 common shares after stockholder approval, subject to ownership caps. Jasper committed to seek approval of the conversion and an increase in authorized common shares within 120 days after closing. The latest 2026 proxy statement is useful for the pre-merger governance baseline, but transaction filings now govern the most important ownership questions.

What opportunities and risks could change Jasper's outlook?

The opportunity is a dense sequence of clinical milestones

The risks are program-specific and capital-structure-specific

The best opportunity is not simply “more pipeline.” It is the possibility that one financing now carries several programs through data readouts that can be partnered, advanced, or stopped based on evidence. The largest risk is that multiple programs consume capital without producing a sufficiently differentiated clinical signal before the runway shortens again.

What matters most in a DCF-style valuation?

A conventional revenue-growth DCF is the wrong starting point

Jasper has no stable revenue base, no positive operating margin, and no mature reinvestment pattern. A useful valuation is therefore a program-level, probability-adjusted model. Each indication needs its own addressable patient population, pricing assumption, launch timing, market share, probability of technical and regulatory success, development cost, commercialization cost, and patent-life window. Corporate cash and liabilities are then added, while future financing dilution is handled explicitly rather than buried in the discount rate.

The most useful KPIs are milestone and cash metrics

ClinicalTrials.gov provides the official registry entry for the KP-104 study. For a research model, registry status, enrollment, endpoints, and completion dates should be reconciled with company guidance each quarter.

What is the key takeaway from Jasper Therapeutics analysis?

Jasper is important as a case study in how a distressed, pre-revenue biotechnology company can use a strategic transaction to reset both its pipeline and its balance sheet. Legacy Jasper entered Q2 2026 with only $14.1 million of cash and substantial doubt about its ability to continue. Within weeks, it reviewed alternatives, acquired Kira, secured a $132 million PIPE, added KP-104 and KP-701, out-licensed two assets for $12 million upfront, and extended its expected runway through the second half of 2028.

For students and MBA readers, Jasper demonstrates why business-model analysis must distinguish operating revenue from financing and why corporate strategy can be inseparable from capital structure. For researchers, it shows the need to separate legacy financial statements from pro forma transaction economics. For investors, the central question is not whether one historical response rate looks attractive; it is whether the combined company can convert a larger portfolio and stronger balance sheet into validated, financeable assets without another destructive reset.